Added to YB: 2024-01-05
Pitch date: 2024-01-05
ESPR [bullish]
Esperion Therapeutics, Inc.
+38.04%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
Market Cap
$807.5M
Pitch Price
$2.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-53.12
P/E
-6.40
EV/Sales
4.33
Sector
Pharmaceuticals
Category
special_situation
$ESPR: Multibagger if two things go its way
ESPR: Broken biotech with revenue generating non-statin cholesterol drug Nexletol. In lawsuit w/ partner Daiichi over milestone payment tied to CV risk reduction. PDUFA 3/31/24 for label expansion, trial 4/15/24. Speculative but potential multi-bagger if catalysts hit H1 '24.
Read full article (1 min)